Results
Oramed Pharmaceuticals Inc.
08/02/2021 | Press release | Distributed by Public on 08/02/2021 14:53
Material Event (Form 8-K)
Other Events.
On July 25, 2021, Oramed Pharmaceuticals Inc. (the 'Company') appointed Michael Rabinowitz, to serve as Chief Commercial Officer, effective August 1, 2021.
Prior to his appointment, from June 1993 until February 2021, Mr. Rabinowitz served in various marketing, sales, business development, and financial leadership roles at the global biopharmaceutical company Merck & Co., where he launched and marketed products in over 30 countries across several disease areas, including launching billion-dollar oral agents in diabetes and managing a global business. Mr. Rabinowitz holds a Masters' Degree from The Carlson School of Management, University of Minnesota. He has also participated in executive health care programs at the Harvard Business School.
Mr. Rabinowitz will be employed by the Company pursuant to an employment agreement. Mr. Rabinowitz's gross annual salary will be $330,000. Mr. Rabinowitz will be eligible for bonuses and equity grants in amounts to be determined at the discretion of the Company's Board of Directors and the Compensation Committee of the Company's Board of Directors, as applicable. In connection with Mr. Rabinowitz's appointment, the Company expects to enter into its standard indemnification agreement with Mr. Rabinowitz, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. Mr. Rabinowitz is not a party to any transactions that are disclosable under Item 404 of Regulation S-K.
1